Department of Radiology, University of Florida College of Medicine Jacksonville, Jacksonville, FL 32209, United States.
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
World J Gastroenterol. 2022 Oct 28;28(40):5827-5844. doi: 10.3748/wjg.v28.i40.5827.
Acinar cell carcinoma (ACC) is a rare pancreatic malignancy with distinctive clinical, molecular, and morphological features. The long-term survival of ACC patients is substantially superior to that of pancreatic adenocarcinoma patients. As there are no significant patient series about ACCs, our understanding of this illness is mainly based on case reports and limited patient series. Surgical resection is the treatment of choice for patients with the disease restricted to one organ; however, with recent breakthroughs in precision medicine, medicines targeting the one-of-a-kind molecular profile of ACC are on the horizon. There are no standard treatment protocols available for people in which a total surgical resection to cure the condition is not possible. As a result of shared genetic alterations, ACCs are chemosensitive to agents with activity against pancreatic adenocarcinomas and colorectal carcinomas. The role of neoadjuvant or adjuvant chemoradiotherapy has not been established. This article aims to do a comprehensive literature study and present the most recent information on acinar cell cancer.
腺泡细胞癌（ACC）是一种罕见的胰腺恶性肿瘤，具有独特的临床、分子和形态学特征。ACC 患者的长期生存率明显优于胰腺腺癌患者。由于关于 ACC 的患者系列没有显著差异，我们对这种疾病的认识主要基于病例报告和有限的患者系列。对于仅局限于一个器官的患者，手术切除是治疗的首选方法；然而，随着精准医学的最新突破，针对 ACC 独特分子特征的药物即将面世。对于那些无法通过手术完全切除来治愈疾病的患者，目前尚无标准的治疗方案。由于存在共同的遗传改变，ACC 对针对胰腺腺癌和结直肠癌的药物具有化疗敏感性。新辅助或辅助放化疗的作用尚未确定。本文旨在进行全面的文献研究，介绍腺泡细胞癌的最新信息。
